significantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD) finance.yahoo.com
When the short is so obvious and everybody is doing it - You have to go long. All short will blow their accounts if not taking proper size.
Hello everyone! Today I have a short term chart analysis for AXSM. You can see the FULL video analysis by clicking the link below in my signature description! I have new updated charts, and new video's every day. Please follow me on tradingview, and subscribe to me on youtube! Leave any questions or comments below, and I will get back to you as soon as possible!
Positive data for one drug trial is not nearly enought to justify such a drastic increase in price.
Warning: High risk pharmaceutical company. I was early in my last chart in January. Chart looks more promising to me now. The company is developing non opioid treatments for joint pain, depression, and Alzheimer's disease. Pipeline (see ling below) is in clinical trials. If trials fail often get large drops in price and vice versa. With the opioid crisis IF these...
Possible double bottom. Watch if holds here. See “the gold bags” post: News today: finance.yahoo.com
Cash: $41 Million (cash runway into the second quarter of 2019) Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018) •Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018) •Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H...
Current share price is testing the upward trending lower resistance line. As the lower resistance line crosses the $5 inflection line we could expect major movement ahead of the Q42017/Q12018 FDA catalysts.
Pushing down against the lower resistance line. Buy ahead of upcoming PDUFA catalyst
Just watching this one unfold in a monster...